Targeting KRASG12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments

Identifying mutations in the KRAS gene has become increasingly important in the treatment of colorectal cancer with many prognostic and therapeutic implications. However, efforts to develop drugs that target KRAS mutations have not been successful until more recently with the introduction of the KRAS(G12C) inhibitors, sotorasib (AMG510) and adagrasib (MRTX849). Both agents have demonstrated safety and promising efficacy in preclinical studies and early phase trials, but it appears that not all tumor types harboring the KRAS(G12C) mutation are sensitive to monotherapy approaches. In particular, patients with colorectal cancer (CRC) derive less benefit compared to those with non-small cell lung cancer (NSCLC), likely due to rapid treatment-induced resistance through increased epidermal growth factor receptor (EGFR) signaling. As a result, combination therapy trials with EGFR inhibitors are currently underway. Here, we will review the available clinical trial data on KRAS(G12C) inhibitors in KRAS(G12C)-mutated CRC, possible mechanisms of resistance to monotherapy, the research studying why available agents are proving to be less efficacious in CRC compared to NSCLC, and future directions for these promising new drugs.

Automated summary

Identifying mutations in the KRAS gene is crucial for the treatment of colorectal cancer. The introduction of KRAS(G12C) inhibitors has shown safety and efficacy in preclinical studies and early phase trials, although not all tumor types with KRAS(G12C) mutations are responsive to monotherapy. Colorectal cancer patients have shown less benefit, possibly due to treatment-induced resistance through increased EGFR signaling. Combination therapy trials with EGFR inhibitors are currently underway.